Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial

The observational prospective trial herein presented aimed at evaluating the efficacy of fulvestrant 500 mg in the treatment of endocrine sensitive advanced breast cancer patients from the real world setting. The primary end point was clinical benefit rate (CBR). Secondary end points were overall su...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Moscetti, Luca, Fabbri, Maria Agnese, Natoli, Clara, Vici, Patrizia, Gamucci, Teresa, Sperduti, Isabella, Iezzi, Laura, Iattoni, Elena, Pizzuti, Laura, Roma, Carmine, Vaccaro, Angela, D’Auria, Giuliana, Mauri, Mariella, Mentuccia, Lucia, Grassadonia, Antonino, Barba, Maddalena, Ruggeri, Enzo Maria
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589600/
https://ncbi.nlm.nih.gov/pubmed/28903361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17262
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires